ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2

NCT ID: NCT05072730

Last Updated: 2024-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-01

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ISAR-CALC 2 trial is an investigator-initiated, prospective, randomized, multicenter, assessors-blind, open-label other clinical investigation. The objective of this trial is to investigate final angiographic minimal lumen diameter (MLD) following a strategy of super high-pressure balloon (OPN NC) versus intravascular lithotripsy (IVL) for drug-eluting stent (DES) implantation in severely calcified coronary lesions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detailed information is provided elsewhere.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calcified Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Super high-pressure balloon (OPN NC)

Patients will be treated with a Super High Pressure percutaneous transluminal coronary angioplasty (PTCA) Balloon (OPN NC).

Group Type EXPERIMENTAL

Super High Pressure Balloon (OPN NC)

Intervention Type DEVICE

Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.

Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion.

Intravascular lithotripsy (IVL)

Patients will be treated with intravascular lithotripsy (IVL).

Group Type EXPERIMENTAL

Intravascular lithotripsy (IVL)

Intervention Type DEVICE

Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.

Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Super High Pressure Balloon (OPN NC)

Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.

Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion.

Intervention Type DEVICE

Intravascular lithotripsy (IVL)

Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.

Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age above 18 years and able to give consent
* Persistent angina despite medical therapy and/or evidence of inducible ischemia
* De-novo lesion in a native coronary artery
* Target reference vessel diameter or intended stent diameter ≥2.50 or ≤4.00 mm by visual estimation
* Severe calcification of the target lesion as determined by visual estimation at coronary angiography
* Unsuccessful lesion preparation with standard non-compliant balloon (\< 30% reduction of baseline diameter stenosis at maximal pressure)
* Written informed consent.

Exclusion Criteria

* Target lesion is located in a coronary artery bypass graft
* Target lesion is an in-stent restenosis
* Target lesion is a chronic total occlusion
* Target vessel thrombus
* Limited long-term prognosis due to other comorbid conditions with life expectancy \<12 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role collaborator

SIS Medical AG

INDUSTRY

Sponsor Role collaborator

Deutsches Herzzentrum Muenchen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Salvatore Cassese, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Deutsches Herzzentrum Munich

Tobias Rheude, MD

Role: PRINCIPAL_INVESTIGATOR

Deutsches Herzzentrum Munich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herz- und Diabeteszentrum NRW Universitätsklinikum der Ruhr-Universität Bochum

Bad Oeynhausen, , Germany

Site Status RECRUITING

Universitätsklinikum Frankfurt

Frankfurt am Main, , Germany

Site Status RECRUITING

MEDICLIN Herzzentrum Lahr

Lahr, , Germany

Site Status RECRUITING

Deutsches Herzzentrum Muenchen

München, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tobias Rheude, MD

Role: CONTACT

+49 89 1218 2985

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohamed Ayoub, MD

Role: primary

David M Leistner, Prof. MD

Role: primary

Kambis Mashayekhi, MD

Role: primary

Salvatore Cassese, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Scalamogna M, Abdel-Wahab M, Mashayekhi K, Fusaro M, Leistner DM, Ayoub M, Xhepa E, Joner M, Kastrati A, Cassese S, Rheude T. Randomized ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2: Design and Rationale of the ISAR-CALC 2 Trial. Cardiovasc Revasc Med. 2023 Apr;49:22-27. doi: 10.1016/j.carrev.2022.12.008. Epub 2022 Dec 30.

Reference Type DERIVED
PMID: 36609101 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GE IDE Nr. BA00421

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Serranator Recoil Study
NCT05161039 UNKNOWN NA
IRIS-Onyx Cohort in the IRIS-DES Registry
NCT02593994 ACTIVE_NOT_RECRUITING
ReZolve2 Clinical Investigation
NCT01845311 COMPLETED NA
VISIBILITY™ Iliac Study
NCT01402700 COMPLETED NA